What the Infectious Disease Physician Needs to Know About Pegylated Interferon and Ribavirin

Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease

(2013) Martin Schaefer et al.   ANNALS OF INTERNAL MEDICINE

Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial

(2012) Maribel Rodriguez-Torres et al.   HIV CLINICAL TRIALS

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

(2012) Anna S. Lok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C

(2011) R. J. de Knegt et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C

(2011) Stefan Zeuzem et al.   HEPATOLOGY

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

(2011) Ira M. Jacobson et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009

(2010) Susan S. Roberts et al.   BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY

Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models

(2010) Emmanuel Thomas et al.   HEPATOLOGY

Prophylactic Treatment With Escitalopram of Pegylated Interferon Alfa-2a–Induced Depression in Hepatitis C

(2010) Crisanto Diez-Quevedo et al.   JOURNAL OF CLINICAL PSYCHIATRY

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

(2010) Edward J Gane et al.   LANCET

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C

(2010) Jacques Fellay et al.   NATURE

Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin

(2009) Jagdish S. Nachnani et al.   ANNALS OF HEMATOLOGY

Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials

(2009) Tahany Awad et al.   HEPATOLOGY

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY

Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia

(2008) Charles L. Bennett   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin

(2008) M. Núñez et al.   JOURNAL OF VIRAL HEPATITIS